Antiviral therapy for chronic HBV during pregnancy
Abstract
Chronic hepatitis B treatment during pregnancy is an extremely difficult task. Regardless immunoprophylaxis a significant proportion of children, born of mothers with high viraemia, is infect-ed with hepatitis B virus. Accumulating data suggests that antiviral therapy is an effective therapy procedure in III trimester for immunoprophylaxis failed. To minimize the counterparts of nucleosi(ti)des impact on embryo antiviral therapy during pregnancy should be prescribed to women at high risk of progressive disease and/ or hepatic decompensation. Currently received safety data gives evidence of telbivudin and tenofovir may be taken during pregnancy. At the same time antiviral therapy requires a careful assessment of risk-benefit ratio.
About the Authors
P. O. Bogomolov
Moscow’s regional research clinical institute n.a. M.F. Vladimirskiy
Russian Federation
Russian Federation
M. V. Matsievich
Moscow’s regional research clinical institute n.a. M.F. Vladimirskiy
Russian Federation
Russian Federation
N. V. Voronkova
Moscow’s regional research clinical institute n.a. M.F. Vladimirskiy
Russian Federation
Russian Federation
O. S. Kuzmina
Podolsk clinical hospital
Russian Federation
Russian Federation
References
1. Alimenti A., Burdge D.R., Ogilvie G.S. [et al.] Lactic acidemia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretroviral therapy // Pediatr. Infect. Dis. J. 2003. Vol. 22, No. 9. P. 782-789.
2. Antiviral Pregnancy Registry (APR). Antiviral Pregnancy Registry Interim Report 1, January 1989 through 31 January 2012. URL: http://APregistry.com2012 (дата обращения: 01.11.2012).
3. Beasley R.P, Stevens C.E., Shiao I.S., Meng H.C. Evidence against breast-feeding as a mechanism for vertical transmission of hepatitis B // Lancet. 1975. Vol. 2 (7938). P. 740-741.
4. Burk R.D., Hwang L.Y., Ho G.Y. [et al.] Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load // J. Infect. Dis. 1994. Vol. 170, No. 6. P. 1418-1423.
5. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection // J. Hepatol. 2012. Vol. 57, No. 1. P. 167-185.
6. Gambarin-Gelwan M. Hepatitis B in pregnancy // Clin. Liver Dis. 2007. Vol. 11, No. 4. P 945-963.
7. Gibb D.M., Kizito H., Russell E.C. [et al.] DART trial team. Pregnancy and infant outcomes among HIV-infected women taking long-term ARTwithandwithout tenofovir in the DART trial // PLoSMed. 2012. Vol. 9, No. 5. P e1001217.
8. Han G.R., Cao M.K., Zhao W. [et al.] A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection // J. Hepatol. 2011. Vol. 55, No. 6. P. 1215-1221.
9. Han G.R., Jiang X.H., Zhao W. [et al.] Lamivudine use in the 2nd or 3rd trimester of pregnancy has similar efficacy in preventing vertical transmission of chronic hepatitis B in highly viremic mothers // Hepatology. 2011. Vol. 54 (S4). P 479A.
10. Hill J.B., Sheffield J.S., Kim M.J. [et al.] Risk of hepatitis B transmission in breast-fed infants of chronic hepatitis B carriers // Obstet. Gynecol. 2002. Vol. 99, No. 6. P. 1049-1052.
11. Lin H.H., Wu WY., Kao J.H., Chen D.S. Hepatitis B post-partum e antigen clearance in hepatitis B carrier mothers: correlation with viral characteristics // J. Gastroenterol. Hepatol. 2006. Vol. 21, No. 3. P. 605-609.
12. Lok A.S.F., McMahon B.J. Chronic hepatitis B: update 2009 // Hepatology. 2009. Vol. 50, No. 3. P. 661-662.
13. Pan C., Zhang H., Pang Q. [et al.] Real world data on the efficacy and safety of telbivudine or lamivudine use in late pregnancy for the prevention of perinatal transmission of hepatitis B virus to the infants // Hepatology. 2012. Vol. 56 (S1). P. 368A.
14. Pan C.Q., Duan Z.P, Bhamidimarri K.R. [et al.] An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus // Clin. Gastroenterol. Hepatol. 2012. Vol. 10, No. 5. P. 452-459.
15. Pan C.Q., Han G.R., Jiang H.X. [et al.] Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B // Clin. Gastroenterol. Hepatol. 2012. Vol. 10, No. 5. P. 520-526.
16. Pan C.Q., Mi L.J., Bunchorntavakul C. [et al.] Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series // Dig. Dis. Sci. 2012. Vol. 57, No. 9. P 2423-2429.
17. Shah I. Lactic acidosis in HIV-exposed infants with perinatal exposure to antiretroviral therapy // Ann. Trop. Paediatr. 2009. Vol. 29, No. 4. P. 257-261.
18. Shaheen A.A., Myers R.P. The outcomes of pregnancy in patients with cirrhosis: a population-based study // Liver Int. 2010. Vol. 30, No. 2. P. 275-283.
19. Söderström A., Norkrans G., Lindh M. Hepatitis B virus DNA
20. Тихоокеанский медицинский журнал, 2015, № 3 during pregnancy and postpartum: aspects on vertical transmission // Scand. J. Infect. Dis. 2003. Vol. 35, No. 11-12. P. 814-819.
21. Tan H.H., Lui H.F., Chow W.C. Chronic hepatitis B virus (HBV) infection in pregnancy. // Hepatol. Int. 2008. Vol. 2, No. 3. P. 370-375.
22. Ter Borg M.J., Leemans W.F., de Man R.A., Janssen H.L. Exacerbation of chronic hepatitis B infection after delivery // J. Viral. Hepat. 2008. Vol. 15, No. 1. P. 37-41.
23. Van Rompay K.K., Hamilton M., Kearney B., Bischofberger N. Pharmacokinetics of tenofovir in breast milk of lactating rhesus macaques // Antimicrob. Agents Chemother. 2005. Vol. 49, No. 5. P. 2093-2094.
24. Weinbaum C.M., Williams I., Mast E.E. [et al.] Centers for Disease Control and Prevention (CDC). Recommendations for identification and public health management of persons with chronic hepatitis B virus infection // MMWR Recomm. Rep. 2008. Vol. 57 (RR-8). P. 1-20.
25. Wiseman E., Fraser M.A., Holden S. [et al.] Perinatal transmission of hepatitis B virus: an Australian experience // Med. J. Aust. 2009. Vol. 190, No. 9. P. 489-492.
26. World Health Organization. Hepatitis B Fact sheet, July 2012. URL: http://www.who.int/mediacentre/factsheets/fs204/ en (дата обращения: 01.11.2012).
27. Xu D.Z., Yan Y.P, Choi B.C. [et al.] Risk factors and mechanism of transplacental transmission of hepatitis B virus: a case-control study // J. Med. Virol. 2002. Vol. 67, No. 1. P. 20-26.
28. Xu WM., Cui Y.T., Wang L. [et al.] Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study // J. Viral. Hepat. 2009. Vol. 16, No. 2. P 94-103.
29. Yang Y.B., Li X.M., Shi Z.J., Ma L. Pregnant woman with fulminant hepatic failure caused by hepatitis B virus infection: a case report // World J. Gastroenterol. 2004. Vol. 10, No. 15. P. 2305-2306.
30. Zou H., Chen Y., Duan Z. [et al.] Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers // J. Viral. Hepat. 2012. Vol. 19, No. 2. P. e18-e25.
Review
For citations:
Bogomolov P.O., Matsievich M.V., Voronkova N.V., Kuzmina O.S. Antiviral therapy for chronic HBV during pregnancy. Pacific Medical Journal. 2015;(3):22-25. (In Russ.)
Views:
181
Email this article 